Read our Recent Headlines

February 23 Biotech Update

The market is looking a little shaky. It is not as if the selling is sending it down but every single spike in the past couple days has been sold..

February 22 Biotech Update

A little pick up in the news flow but clearly the sector has been tied to the broader market in the immediate term. The spike in interest rates caused by.

February 21 Biotech Update

There is not a lot of news to start the day, so this can be relatively quick. In general, it seems that the market is slowly getting back to a.

February 20 Biotech Update

There is some news to start the week but mainly some minor partnerships and some data. Not the large scale M&A that people always seem to hope for after a.

February 16 Biotech Update

There has been some interesting news to end the week. The market seems to have recovered its footing a little and this includes the sector. There is still some work.

Dave Trading – March 2018

*** David Sobek is a disciplined value investor.  Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.

February 14 Biotech Update

It is a pretty active morning for news, so I will dive right into the events as they are pretty interesting. I am not convinced that these will be enough.


Quick Facts














Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!